Press Release FeedGet the RSS feed
Menu

Business Wire

Ingenia Therapeutics Nominated for Both the Prix Galien USA and the Inaugural Prix Galien Korea for Best Startup

Business Wire

WATERTOWN, Mass., August 19, 2026--Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, today announced that it has been nominated for the Prix Galien USA and the inaugural Prix Galien Korea, both in the Best Startup category by The Galien Foundation. The Galien Foundation is the premier global institution recognizing and awarding outstanding achievements of innovators in life sciences.

The dual recognition arrives alongside a defining milestone for Ingenia: its initial public offering on the KOSDAQ on August 18th. Together, the nominations underscore the global momentum behind the company's proprietary TIE-body and LCIDEC platforms, which are built on a fundamental breakthrough in vascular biology, the direct, ligand-independent activation of the TIE2 pathway to restore the vascular barrier.

"To be recognized in both the United States and Korea is a tremendous honor and a reflection of our team's commitment to global innovation," said Sangyeul Han, PhD, CEO of Ingenia Therapeutics. "As a US company listed on KOSDAQ, we are proud to bridge both markets, and these nominations affirm the potential of our direct TIE2 activation technology to meaningfully advance the treatment of vascular-driven diseases, and they strengthen our commitment to bringing these therapies to patients faster."

Ingenia's pipeline is anchored by two clinical-stage programs: MK-8748 (Tiespectus), an investigational bispecific antibody (Anti-VEGF/TIE2) advancing into Phase 3 for patients with neovascular age-related macular degeneration (nAMD) and patients with diabetic macular edema (DME) through its collaboration with Merck (known as MSD outside of the US and Canada); and IGT-303, progressing through Phase 1/2a trials across Australia, New Zealand, and South Korea for chronic kidney disease (CKD).

About Ingenia Therapeutics

Ingenia Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class therapies that restore the vascular stability. Headquartered in Watertown, MA, USA, with operations in South Korea and Australia, the company leverages its expertise in antibody engineering to target the TIE2 pathway across ophthalmology, nephrology, oncology and other high-value therapeutic areas, including CNS and Cardiovascular & Pulmonary diseases.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of applicable securities laws, including, without limitation, statements regarding Ingenia Therapeutics' business strategy, research and development plans, clinical trial initiation and completion timelines, regulatory submissions and approvals, commercialization plans, anticipated milestones, projected financial performance, expected revenue, including potential milestone, royalty, or other payments from existing or future collaborations with Merck, EyeBio, or other partners.

  1. FinanceArcus Biosciences, Inc.Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common StockCompanies: Jefferies Financial GroupHAYWARD, Calif., October 22, 2026--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatment of cancer and immune diseases, today announced the pricing of an underwritten public offering of 14,
  2. RetailOptionMetrics Exhibiting at Asia EQDAs APAC options volume increases and retail options trading intensifies overall, leading options data and analytics provider offers derivatives professionals insights on leveraging options data to assess alpha and risk NEW YORK, October 22, 2026--OptionMetrics , the leading historical options data and
  3. ValueAct CapitalValueAct Calls for an Extraordinary General Meeting of Takara Holdings to Strengthen the Board and Hold Incumbent Outside Directors Accountable for Failure to Supervise ManagementSees significant untapped potential in Takara Holdings that more focused strategy and management execution could unlock. Seeks to hold incumbent Outside Directors accountable for the long-term underperformance of the Company and the Board's persistent failure to effectively supervise management. Proposes the election of t
  4. BankingTriad Business BankTriad Business Bank Responds to M&F’s October 19 StatementThe agreement says M&F Bank "will cease to be an independent bank." The meeting moved, but the facts didn't. M&F's Board decided the bank was finished. A new day is here, and Triad is just getting started: it responds to M&F's October 19 statement, corrects the record on its proposal, and keeps M&F alive for its sharehold
  5. FinanceBlackRock Capital Allocation Term TrustBlackRock Capital Allocation Term Trust (BCAT) Announces Results of its Rights OfferingCompanies: BlackRockNEW YORK, October 22, 2026--BlackRock Capital Allocation Term Trust (NYSE: BCAT) (the "Fund") today announced the successful completion of its transferable rights offer (the "Offer") which expired on October 21, 2026 (the "Expiration Date"). The Offer entitled rights holders to subscribe for up to an a
  6. InsuranceAM Best to Host Networking Reception at International Association of Insurance Supervisors’ Annual Conference in Hong KongOLDWICK, N.J., October 22, 2026--AM Best will host a networking reception in conjunction with the International Association of Insurance Supervisors' (IAIS) annual conference at the Harbour Grand Kowloon in Hong Kong on 11 November 2026 at 6:00 p.m. (HKT). The AM Best reception will be in the Grand Sa